Zevra Therapeutics Stock Quote ZVRA - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

4.80

Bid

4.80

Ask

5.55

Volume

191,945

4.76 Day's Range 5.00

3.89 52 Week Range 7.28

Market Cap

173.847M

Previous Close

4.89

Open

4.94

Last Trade

4.93

Last Trade Time

Financial Volume

$ 934,167

VWAP

4.8668

Average Volume (3m)

239,710

Shares Outstanding

36,218,164

Dividend Yield

PE Ratio

-3.78

Earnings Per Share (EPS)

-1.27

Revenue

27.46M

Net Profit

-46.05M

Zevra Therapeutics, Inc. is a rare disease therapeutics company. The Company is engaged in creating therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical-stage pipeline and ... Zevra Therapeutics, Inc. is a rare disease therapeutics company. The Company is engaged in creating therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical-stage pipeline and commercial stage assets. It employs its LAT platform technology to create a portfolio of approved products. Its product candidates include Arimoclomol, KP1077IH, KP1077N and AZSTARYS. Arimoclomol is an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate, which is being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy. KP1077 is comprised solely of serdexmethylphenidate (SDX), the Company's prodrug of d-methylphenidate (d-MPH). AZSTARYS is a prodrug for the treatment of ADHD in patients aged six years or older. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.kempharm.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Zevra Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ZVRA. The last closing price for Zevra Therapeutics was $4.89. Over the last year, Zevra Therapeutics shares have traded in a share price range of $ 3.89 to $ 7.28.

Zevra Therapeutics currently has 36,218,164 shares outstanding. The market capitalization of Zevra Therapeutics is $173.85 million. Zevra Therapeutics has a price to earnings ratio (PE ratio) of -3.78.

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Zevra Therapeutics to Participate at Upcoming Investor Events

CELEBRATION, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane...

Form 8-K - Current report

Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates

Full commercial launch of OLPRUVA at the end of January 2024, with market access growing to ~75% of covered lives as of May 1, 2024 Arimoclomol NDA review underway with PDUFA date of September...

Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024

CELEBRATION, Fla., May 01, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that it will host a...

Zevra Therapeutics’ President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024

CELEBRATION, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that Neil F...

Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting

The oral presentation highlighted data from Zevra’s Expanded Access Program demonstrating a consistent safety profile CELEBRATION, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.36	-6.97674418605	5.16	5.3	4.74	266318	5.00880992	CS
4	0.055	1.15911485774	4.745	5.3	4.39	200927	4.77625533	CS
12	-2.1	-30.4347826087	6.9	7.28	4.39	239710	5.54003893	CS
26	0.5	11.6279069767	4.3	7.28	4.11	252176	5.58457807	CS
52	0.55	12.9411764706	4.25	7.28	3.89	229026	5.36649248	CS
156	-0.85	-15.0442477876	5.65	7.28	3.89	234608	5.31856288	CS
260	-0.85	-15.0442477876	5.65	7.28	3.89	234608	5.31856288	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
CTNTCheetah Net Supply Chain Service Inc	$ 6.58 (452.94%)	49.59M
FFIEFaraday Future Intelligent Electric Inc	$ 0.2849 (367.05%)	1.57B
MTCMMTec Inc	$ 9.10 (87.63%)	4.22M
HOLOMicroCloud Hologram Inc	$ 3.2201 (61.01%)	105.54M
SPWRSunPower Corporation	$ 4.39 (59.64%)	137.69M
AUGXAugmedix Inc	$ 1.14 (-51.28%)	13.06M
NOTVInotiv Inc	$ 2.12 (-49.16%)	4.02M
SHIMShimmick Corporation	$ 2.395 (-34.20%)	235.69k
AKYAAkoya BioSciences Inc	$ 2.90 (-29.61%)	2.21M
EASTEastside Distilling Inc	$ 1.0777 (-27.67%)	208.9k
FFIEFaraday Future Intelligent Electric Inc	$ 0.2849 (367.05%)	1.57B
CRKNCrown Electrokinetics Corporation	$ 0.0476 (3.93%)	390.01M
GWAVGreenwave Technology Solutions Inc	$ 0.0443 (6.24%)	238.8M
PLUGPlug Power Inc	$ 3.445 (19.20%)	203.42M
SINTSiNtx Technologies Inc	$ 0.054 (39.18%)	157.36M